Abstracts Archive - Page 1888 of 2425 - ACR Meeting Abstracts

Abstract Number: 2470 • 2014 ACR/ARHP Annual Meeting
Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Adalimumab (ADA) showed highly efficacious in rheumatoid arthritis (RA) in the clinical trials, although there is little evidence in daily clinical practice.The clinical usefulness…
Abstract Number: 2469 • 2014 ACR/ARHP Annual Meeting
The Efficacy and Safety of Tocilizumab Subcutaneous Q2W and Following Escalation from Q2W to QW Therapy in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis at 96 Weeks
Alan Kivitz¹, Ewa Olech², Michael A. Borofsky³, Beatriz M. Zazueta⁴, Federico Navarro-Sarabia⁵, S. C. Radominski⁶, Joan T. Merrill⁷, Jinglan Pei⁸, Lucy Rowell⁹, Clare Nasmyth-Miller⁹, Sunethra Wimalasundera⁹ and Janet E. Pope¹⁰, ¹Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ²Internal Medicine, Division of Rheumatology, University of Nevada School of Medicine, Las Vegas, NV, ³Clinical Research Center of Reading, Reading, PA, ⁴Reumatologia, Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, ⁵Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Genentech, South San Francisco, CA, ⁹Roche, Welwyn Garden City, United Kingdom, ¹⁰St Joseph Health Care, London, ON, Canada
Background/Purpose : The BREVACTA study assessed the efficacy and safety of subcutaneous tocilizumab (TCZ SC) in patients (pts) with RA who had an inadequate response…
Abstract Number: 2468 • 2014 ACR/ARHP Annual Meeting
Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis
Gerd Burmester¹, Daniel E. Furst², B G Combe³, T W J Huizinga⁴, Vivian P. Bykerk⁵, D Wong⁶, C S Karyekar⁶ and P Emery⁷, ¹Charité – University Medicine Berlin, Berlin, Germany, ²University of California at Los Angeles, Los Angeles, CA, ³Montpellier University Hospital, Montpellier, France, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Clinical remission is associated with better long-term outcomes1,2 and should be the goal of therapy in RA. In the Assessing Very Early Rheumatoid arthritis…
Abstract Number: 2467 • 2014 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab in Biologics NaÃ¯ve RA Patients – Interim Analysis of PMS for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-NaÃ¯ve RA Patients Study
Naoki Ishiguro¹, Tatsuya Atsumi², Masayoshi Harigai³, Tsuneyo Mimori⁴, Norihiro Nishimoto⁵, Takayuki Sumida⁶, Tsutomu Takeuchi⁷, Yoshiya Tanaka⁸, Nobuhiro Takagi⁹, Kunihiko Tanaka¹⁰ and Hisashi Yamanaka¹¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Medicine II School of Medicine, Hokkaido University, Sapporo, Japan, ³Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁵Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka, Japan, ⁶Dept Internal Medicine, Univ of Tsukuba/Inst Clin Med, Tsukuba City, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁸First Dept of Internal Med, U Occupa & Environ Hlth, Kitakyushu, Japan, ⁹Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ¹⁰Pharmacovigilance, Chugai Pharmaceutical, Tokyo, Japan, ¹¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The all-patient PMS study of tocilizumab (TCZ) followed 7901 RA patients for 28 wks. That study (hereafter, PMS7901) showed patients with a high probability…
Abstract Number: 2453 • 2014 ACR/ARHP Annual Meeting
High-Density Genotyping of Risk Loci in African Americans with RA
Maria I. Danila¹, Richard Reynolds², Qi Yan³, Nianjun Liu³, Peter K. Gregersen⁴, CLEAR Investigators², Donna K. Arnett² and S. Louis Bridges Jr.^2,5, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Genetic studies have identified 101 risk loci for RA in individuals of Caucasian and Asian descent. However, to date the genetic determinants of RA…
Abstract Number: 2454 • 2014 ACR/ARHP Annual Meeting
Genetic Influences on Rheumatoid Arthritis in African-Americans
Vincent A. Laufer^1,2, Richard J. Reynolds³, Maria I. Danila⁴, Gordon Wu⁵, Amit Patki⁵, Devin Absher⁶, Carl D. Langefeld⁷, R. Curtis Hendrickson⁸, Elliot J. Lefkowitz⁹, Ted R. Mikuls¹⁰, Peter K. Gregersen¹¹, Elizabeth E. Brown⁸, Robert P. Kimberly⁸, John B. Harley¹², Donna K. Arnett⁸, Hemant K. Tiwari⁵ and S. Louis Bridges Jr.^8,13, ¹Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham Medical Scientist Training Program, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁶Hudson Alpha Institute for Biotechnology, Huntsville, AL, ⁷Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Microbiology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹¹Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, ¹²Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatoid arthritis (RA) affects 0.5-1% of the population worldwide. The genetics of RA has been analyzed in large European and Asian studies, but much…
Abstract Number: 2455 • 2014 ACR/ARHP Annual Meeting
IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression
Erika Noss¹, Sook Kyung Chang², Gerald Watts² and Michael Brenner², ¹Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Interleukin (IL)-6 is an important driver of rheumatoid arthritis (RA) pathology, and synovial fibroblasts are a major source of IL-6 in the RA synovium. …
Abstract Number: 2456 • 2014 ACR/ARHP Annual Meeting
Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression
Marshall Davis¹, Tricia LeVan², Fang Yu³, Harlan Sayles⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Kaleb Michaud⁷, Geoffrey M Thiele⁸ and Ted R. Mikuls⁴, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Univ of Nebraska Med Ctr, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷National Data Bank for Rheumatic Diseases, Wichita, KS, ⁸Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Toll-like receptor (TLR)-4 signaling pathways have been implicated in both the innate and adaptive immune responses that characterize rheumatoid arthritis (RA). In this study,…
Abstract Number: 2457 • 2014 ACR/ARHP Annual Meeting
Anti-Major Histocompatibility Complex Class I-Related Chain a (MICA) Antibodies in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Hiroshi Furukawa¹, Shomi Oka¹, Kota Shimada², Akiko Komiya¹, Naoshi Fukui¹, Naoyuki Tsuchiya³ and Shigeto Tohma¹, ¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ³Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated RA-associated ILD (RA-ILD) that influences the prognosis of the disease.…
Abstract Number: 2458 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments
Yoshinobu Koyama¹, Motohiko Tanino², Shuji Nagano³, Toshiyuki Ota³ and Toshie Higuchi¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc., Yokohama, Japan, ³Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan
Background/Purpose The advances in understanding of the molecular nature of immune cell receptors enabled to offer new oral, targeted therapies. Tofacitinib (TOF) is the first…
Abstract Number: 2459 • 2014 ACR/ARHP Annual Meeting
Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis
Fernanda Genre¹, Raquel López-Mejías¹, Mercedes García-Bermúdez², Santos Castañeda³, Carlos González-Juanatey⁴, Javier Llorca⁵, Alfonso Corrales¹, Begoña Ubilla¹, Jose A. Miranda-Filloy⁶, Encarnación Amigo⁶, Trinitario Pina Murcia¹, Carmen Gómez-Vaquero⁷, Luis Rodriguez-Rodriguez⁸, Benjamin Fernández Gutierrez⁸, Alejandro Balsa⁹, Dora Pascual-Salcedo⁹, Francisco Javier López-Longo¹⁰, Patricia Carreira¹¹, Ricardo Blanco¹², Isidoro González-Alvaro¹³, Javier Martin¹⁴ and Miguel A González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁷Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁸Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ⁹Hospital Universitario La Paz, Department of Rheumatology, Madrid, Spain, ¹⁰Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, ¹¹Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ¹²Hospital Marques de Valdecilla, Santander, Spain, ¹³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁴Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Rheumatoid arthritis is an inflammatory disease with a high incidence of cardiovascular disease due to accelerated atherosclerosis. Osteoprotegerin (OPG) has been associated with an…
Abstract Number: 2460 • 2014 ACR/ARHP Annual Meeting
Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4⁺ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis
Amy E. Anderson¹, Arthur G Pratt¹, Mamdouh Sedhom², Nisha Nair³, Jonathan Massey³, Christine Routledge¹, Ben Hargreaves¹, Philip Brown¹, Anne Barton⁴, John D Isaacs¹ and Ranjeny Thomas², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Translational Research Institute, The University of Queensland Diamantina Institute, Queensland, Australia, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Early diagnosis of rheumatoid arthritis (RA) improves outcomes but is challenging, particularly amongst anti-citrullinated peptide auto-antibody (ACPA) negative individuals. Previously we identified an IL-6…
Abstract Number: 2461 • 2014 ACR/ARHP Annual Meeting
Osteprotegerin Concentrations Are Independently Related to Established Cardiovascular Disease in Rheumatoid Arthritis
Raquel López-Mejías¹, Begoña Ubilla¹, Fernanda Genre¹, Alfonso Corrales¹, José L Hernandez², Ivan Ferraz-Amaro³, Linda Tsang⁴, Javier Llorca⁵, Ricardo Blanco⁶, Carlos González-Juanatey⁷, MA González-Gay^1,4 and Patrick H Dessein⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Department of Internal Medicine, Hospital Universitario Marques de Valdecilla, University of Cantabria, RETICEF, IDIVAL, Santander, Spain, ³Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ⁴Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain
Background/Purpose: We determined whether osteoprotegerin (OPG) concentrations are associated with established cardiovascular disease (CVD) amongst patients with rheumatoid arthritis (RA). Methods: OPG concentrations were measured…
Abstract Number: 2462 • 2014 ACR/ARHP Annual Meeting
Centrosomal Protein 70kDa Is Down-Regulated By Decoy Receptor 3 in Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda^1,2, Yasushi Miura^2,3, Toshihisa Maeda², Shinya Hayashi² and Masahiro Kurosaka², ¹Orthopaedic Surgery, Kakogawa City Hospital, Kakogawa, Japan, ²Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand, LIGHT, and…
Abstract Number: 2463 • 2014 ACR/ARHP Annual Meeting
Stromal Cell Markers Are Differentially Expressed in the Synovial Tissue of Patients with Early Arthritis
Ivy Y.K. Choi¹, Olga N. Karpus², Jason D. Turner³, Debbie L. Hardie³, Maria J. H. de Hair¹, Karen I. Maijer¹, Paul-Peter Tak^1,4,5, Karim Raza^3,6, Jörg Hamann², Christopher Buckley³, Danielle Marie Gerlag^1,7 and Andrew Filer^3,8, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁴GlaxoSmithKline, Stevenage, United Kingdom, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁷GlaxoSmithKline, Cambridge, United Kingdom, ⁸University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose Previous studies have shown increased expression of stromal markers in synovial tissue (ST) of patients with established rheumatoid arthritis (RA). Here, the expression of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].